Morgan Stanley raised the firm’s price target on Fresenius SE (FSNUY) to EUR 41 from EUR 40 and keeps an Overweight rating on the shares.

Deutsche Bank raised the firm’s price target on Fresenius SE (FSNUY) to EUR 44 from EUR 42 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate source for real-time, ...

The healthcare company lifted its full-year guidance after a robust third quarter driven by Kabi and good organic growth at ...

DaVita’s strong services face risks from debt and economic uncertainties. Find out why DVA stock is a "Hold" with a $130 ...

Third Quarter 2024 Results Key Financial Results Revenue: €5.37b (up 3.5% from 3Q ...

Fresenius SE’s historical prowess in dialysis and injectable therapies has created opportunities to vertically integrate into several medical service and technology businesses by organic and ...

Deutsche Bank raised the firm’s price target on Fresenius SE (FSNUY) to EUR 44 from EUR 42 and keeps a Buy rating on the shares. The views and opinions expressed herein are the views and ...

Narrow-moat Fresenius SE turned in strong third-quarter results helped by rising medical utilization, and management increased its 2024 outlook ranges. To account for recent cash flow generated ...

The presentation was e-mailed to our distribution list earlier today and is available on fresenius.com. On Slide 2 of the presentation, you'll find the usual safe harbor statement. Unless stated ...

JPMorgan raised the firm’s price target on Fresenius SE (FSNUY) to EUR 41.90 from EUR 40.10 and keeps an Overweight rating on the shares. The views and opinions expressed herein are the views ...